ticker,date,drug,stage
EARS,11/30/2017,AM-111 HEALOS,Phase 3
AMGN,12/02/2017,Repatha,PDUFA
MYL,12/03/2017,MYL-1401O - trastuzumab biosimilar,PDUFA
ZGNX,12/03/2017,ZX008 - (Study 1),Phase 3
LOXO,12/04/2017,Larotrectinib (LOXO-101),Phase 2
IMMU,12/05/2017,SACTUZUMAB GOVITECAN (IMMU-132),Phase 3
JNJ,12/05/2017,Rilpivirine and Dolutegravir,PDUFA priority review
NVO,12/05/2017,Semaglutide,PDUFA
CASC,12/07/2017,(Tucatinib ONT-380) and T-DM1,Phase 1b
AFMD,12/09/2017,AFM13 with Keytruda,Phase 1b
AKTX,12/09/2017,Coversin,Phase 2
ARGX,12/09/2017,ARGX-110,Phase 2
ARGX,12/09/2017,ARGX-110,Phase 1/2
BLCM,12/09/2017,BPX-501,Phase 1/2
CBIO,12/09/2017,CB 2679d/ ISU304,Phase 1/2
CELG,12/09/2017,JCAR017,Phase 1/2
CLLS,12/09/2017,UCART19 (PALL),Phase 1
MGNX,12/09/2017,Flotetuzumab,Phase 1
STML,12/09/2017,SL-401,Phase 2
XLRN,12/09/2017,Sotatercept,Phase 2
AGIO,12/10/2017,AG-348,Phase 2
ATNM,12/10/2017,Actimab-A,Phase 2
BLUE,12/10/2017,LentiGlobin - HGB-206,Phase 1/2
CELG,12/10/2017,CC-122,Phase 1/2
CPRX,12/10/2017,Firdapse,Phase 3
FBIO,12/10/2017,CAEL‐101,Phase 1/2
IMDZ,12/10/2017,G100,Phase 2
KDMN,12/10/2017,KD025,Phase 2
KURA,12/10/2017,Tipifarnib,Phase 2
KURA,12/10/2017,Tipifarnib,Phase 2
STML,12/10/2017,SL-401,Phase 2
TGTX,12/10/2017,TGR-1202,Phase 1/2
AGIO,12/11/2017,Ivosidenib,Phase 1
AGIO,12/11/2017,Ivosidenib,Phase 1
ALXN,12/11/2017,ALXN1210,Phase 1/2
BLUE,12/11/2017,bb2121,Phase 1
BPMC,12/11/2017,BLU-285,Phase 1/2
CELG,12/11/2017,bb2121,Phase 1
FATE,12/11/2017,ProTmune - PROTECT,Phase 1/2
GBT,12/11/2017,GBT440 HOPE-KIDS 1,Phase 2a
GERN,12/11/2017,Imetelstat - IMerge Study,Phase 2/3
GLYC,12/11/2017,GMI-1271,Phase 1/2
JUNO,12/11/2017,JCAR017,Phase 1/2
ONCE,12/11/2017,SPK-8011,Phase 1/2
TRIL,12/11/2017,TTI-621,Phase 1
ABBV,12/12/2017,Venclexta (MURANO),Phase 3
JNJ,12/12/2017,DARZALEX (Daratumumab) - ALCYONE,Phase 3
STML,12/12/2017,SL-401,Phase 2
GALT,12/15/2017,GR-MD-02,Phase 2b
ACRS,12/24/2017,A-101,PDUFA
AGRX,12/26/2017,Twirla,PDUFA
CORI,12/26/2017,Twirla,PDUFA
VRX,12/27/2017,Luminesse,PDUFA
AEZS,12/30/2017,Macimorelin Acetate - Macrilen,PDUFA
ABBV,12/31/2017,Risankizumab,Phase 2b
ADRO,12/31/2017,CRS-207 with pembrolizumab,Phase 2
BIIB,12/31/2017,BAN2401 (Aβ mAb),Phase 2
BPTH,12/31/2017,Prexigebersen,Phase 2
BYSI,12/31/2017,Plinabulin (Trial 105),Phase 2/3
CALA,12/31/2017,CB-839 with paclitaxel,Phase 2
CELG,12/31/2017,REVLIMID - RELEVANCE,Phase 3
CELG,12/31/2017,OTEZLA,Phase 2
CELG,12/31/2017,GED-0301,Phase 2
CLRB,12/31/2017,CLR 131,Phase 2
DCTH,12/31/2017,Melphalan Hepatic Delivery System (Melphalan HDS),Phase 3
EDGE,12/31/2017,EG-1962,Phase 3
EGLT,12/31/2017,Egalet-002,Phase 3
GILD,12/31/2017,GS-9674,Phase 2
IRWD,12/31/2017,IW-1973,Phase 2a
IRWD,12/31/2017,IW-1973,Phase 2
KALA,12/31/2017,INVELTYS,Phase 3
KALA,12/31/2017,INVELTYS,Phase 3
MDGL,12/31/2017,MGL-3196,Phase 2
MLNT,12/31/2017,Taksta - Fusidic acid,Phase 2/3
MRK,12/31/2017,Ertugliflozin,PDUFA
MRSN,12/31/2017,XMT1522,Phase 1
NLNK,12/31/2017,Indoximod + gemcitabine and nab-paclitaxel,Phase 2
NVAX,12/31/2017,NanoFlu vaccine,Phase 1/2
OCRX,12/31/2017,OCR-002,Phase 2a
OGEN,12/31/2017,AG013,Phase 2
PBYI,12/31/2017,Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL,Phase 2
PFE,12/31/2017,Xeljanz,Phase 3
PFE,12/31/2017,Ertugliflozin,Phase 3
PFE,12/31/2017,BOSULIF,PDUFA priority review
PHMMF,12/31/2017,Zepsyre(PM1183),Phase 3
PTI,12/31/2017,PTI-428,Phase 2
RARX,12/31/2017,RA101495,Phase 2
RDUS,12/31/2017,Elacestrant,Phase 2b
REGN,12/31/2017,EYLEA + nesvacumab,Phase 2
REGN,12/31/2017,EYLEA + nesvacumab,Phase 2
RETA,12/31/2017,Omaveloxolone - REVEAL,Phase 1/2
RGNX,12/31/2017,RGX-501,Phase 1/2
RNN,12/31/2017,Supinoxin,Phase 2a
RNN,12/31/2017,RX-3117,Phase 2
RNN,12/31/2017,Archexin,Phase 2a
RVNC,12/31/2017,RT002 - SAKURA 2,Phase 3
RVNC,12/31/2017,RT002,Phase 2
RVNC,12/31/2017,RT002 - SAKURA 1,Phase 3
RXII,12/31/2017,RXI-109-1402,Phase 2
RXII,12/31/2017,Samcyprone - RXI-SCP-1502,Phase 2
SAGE,12/31/2017,SAGE-217,Phase 2
SAGE,12/31/2017,SAGE-217,Phase 2
TCON,12/31/2017,TRC105,Phase 2
VKTX,12/31/2017,VK5211,Phase 2
VNDA,12/31/2017,HETLIOZ (tasimelteon),Phase 2
XENT,01/07/2018,RESOLVE steroid-releasing implant,PDUFA
EIGR,01/08/2018,Ubenimex - LIBERTY,Phase 2
BOLD,01/10/2018,AT132 - ASPIRO,Phase 1/2
LLY,01/10/2018,Abemaciclib - MONARCH 1 and 2,PDUFA priority review
LPCN,01/10/2018,LPCN 1021,PDUFA
ONCE,01/12/2018,Luxturna (voretigene neparvovec),PDUFA priority review
AXSM,01/15/2018,AXS-02 CREATE-1,Phase 3
AXSM,01/15/2018,AXS-02 COAST-1,Phase 3
BLRX,01/18/2018,BL-8040 in combination with KEYTRUDA - COMBAT trial,Phase 2
EXEL,01/19/2018,XL184 cabozantinib (CELESTIAL),Phase 3
SGYP,01/24/2018,Trulance (plecanatide),PDUFA
AAAP,01/26/2018,Lutathera,PDUFA
ARDM,01/26/2018,Linhaliq (Pulmaquin),PDUFA priority review
SCMP,01/28/2018,Lubiprostone,PDUFA
AST,01/31/2018,AST-OPC1 SCiSTAR,Phase 1/2
AXON,01/31/2018,Intepirdine,Phase 2
AXON,01/31/2018,Intepirdine - HEADWAY-DLB,Phase 2b
AXON,01/31/2018,Nelotanserin,Phase 2
KDMN,01/31/2018,KD025,Phase 2
PFE,01/31/2018,Talazoparib,Phase 3
XLRN,01/31/2018,ACE-083,Phase 2
AMAG,02/02/2018,Feraheme,PDUFA
PTLA,02/02/2018,Andexanet alfa,PDUFA
AMGN,02/03/2018,XGEVA,PDUFA
GILD,02/12/2018,Bictegravir/F/TAF,PDUFA priority review
AMAG,02/14/2018,Makena - auto injector,PDUFA
ATRS,02/14/2018,Makena - auto injector,PDUFA
PCRX,02/14/2018,EXPAREL,PDUFA
EXEL,02/15/2018,Cabozantinib - CABOSUN,PDUFA priority review
KURA,02/15/2018,Tipifarnib,Phase 2
APRI,02/17/2018,Vitaros,PDUFA
KMPH,02/23/2018,KP201/APAP,PDUFA
AERI,02/28/2018,Rhopressa,PDUFA
AZN,02/28/2018,Lynparza,PDUFA priority review
CRMD,02/28/2018,Neutrolin - LOCK-IT 100,Phase 3
IONS,02/28/2018,IONIS-HTT Rx,Phase 1/2
LJPC,02/28/2018,LJPC-501,PDUFA priority review
MDGL,02/28/2018,MGL-3196,Phase 2
MRK,02/28/2018,Lynparza,PDUFA priority review
MRNS,02/28/2018,Ganaxolone,Phase 2
ONTX,02/28/2018,IV Rigosertib - INSPIRE,Phase 3
RXII,02/28/2018,RXI-109-1501,Phase 1/2
SRNE,02/28/2018,ZTlido (lidocaine patch 1.8%),PDUFA
VRTX,02/28/2018,Tezacaftor (VX-661) / ivacaftor,PDUFA priority review
OTIC,03/02/2018,OTIPRIO,PDUFA
BMY,03/05/2018,Opdivo -  4 week applications,PDUFA
PFE,03/13/2018,Xeljanz,PDUFA
BIIB,03/30/2018,Natalizumab (α4-integrin inhibitor),Phase 2b
ABIO,03/31/2018,Gencaro - GENETIC-AF trial,Phase 2b
ACOR,03/31/2018,Tozadenant,Phase 3
AIMT,03/31/2018,AR101 PALISADE,Phase 3
ALT,03/31/2018,NasoVAX,Phase 1/2
ANAB,03/31/2018,ANB020,Phase 2a
ANTH,03/31/2018,Sollpura - RESULT,Phase 3
ARGX,03/31/2018,ARGX-113,Phase 2
ARNA,03/31/2018,APD371,Phase 2
ARNA,03/31/2018,Etrasimod,Phase 2
AVEO,03/31/2018,TIVO-3 - tivozanib,Phase 3
AXON,03/31/2018,Nelotanserin,Phase 2
BMY,03/31/2018,CM-227 – Opdivo + Yervoy,Phase 3
CDTX,03/31/2018,Rezafungin (CD101) IV - STRIVE,Phase 2
CELG,03/31/2018,REVLIMID - AUGMENT NHL-007,Phase 3
CLBS,03/31/2018,CLBS03,Phase 2
CLSD,03/31/2018,Suprachoroidal CLS-TA - PEACHTREE,Phase 3
CORT,03/31/2018,CORT125134,Phase 2
CYTK,03/31/2018,CK-2127107,Phase 2
DERM,03/31/2018,Olumacostat glasaretil (DRM01),Phase 3
EARS,03/31/2018,Keyzilen (AM-101) - TACTT3,Phase 3
ESPR,03/31/2018,Bempedoic Acid - 1002-039,Phase 2
EYEG,03/31/2018,EGP-437,Phase 2b
FGEN,03/31/2018,Pamrevlumab (FG-3019),Phase 2
GALE,03/31/2018,NeuVax in combination with Herceptin,Phase 2b
GERN,03/31/2018,Imetelstat - IMbarkStudy,Phase 2
GILD,03/31/2018,GS-9674,Phase 2
GILD,03/31/2018,GS-9674,Phase 2
GILD,03/31/2018,Entospletinib,Phase 2
GLMD,03/31/2018,Aramchol - ARRIVE,Phase 2
GSK,03/31/2018,Dolutegravir + lamivudine (GEMINI 1),Phase 3
GTHX,03/31/2018,Trilaciclib,Phase 2
GWPH,03/31/2018,GWP42006 (CBDV),Phase 2
IMRN,03/31/2018,IMM-124E,Phase 2
MBIO,03/31/2018,MB-102,Phase 1
MBIO,03/31/2018,MB-101,Phase 1
MCRB,03/31/2018,SER-262,Phase 1b
MESO,03/31/2018,MPC-150-IM - Class IV,Phase 2b
MESO,03/31/2018,MSC-100-IV,Phase 3
MRK,03/31/2018,(MK-3475-189/KEYNOTE-189),Phase 3
MRTX,03/31/2018,Mocetinostat and durvalumab,Phase 2
MYOK,03/31/2018,MYK-461 - PIONEER-HCM,Phase 2
OBSV,03/31/2018,OBE001 - IMPLANT2,Phase 2
OHRP,03/31/2018,OHR-102 (MAKO),Phase 3
PFE,03/31/2018,Tanezumab,Phase 3
PFE,03/31/2018,Tanezumab,Phase 3
PLX,03/31/2018,OPRX-106,Phase 2
PTGX,03/31/2018,PTG-100,Phase 2b
RARE,03/31/2018,DTX301,Phase 1/2
REGN,03/31/2018,Praluent (alirocumab) ODYSSEY OUTCOMES,Phase 3
RETA,03/31/2018,Bardoxolone methyl - LARIAT,Phase 2
RETA,03/31/2018,Omaveloxolone - MOTOR,Phase 2
RGLS,03/31/2018,RG-012,Phase 1/2
SAGE,03/31/2018,SAGE-217,Phase 2
SMMT,03/31/2018,Ezutromid,Phase 2
SNY,03/31/2018,SAR439684 (PD-1),Phase 2
SNY,03/31/2018,Praluent (alirocumab) ODYSSEY OUTCOMES,Phase 3
SPHS,03/31/2018,Topsalysin (PRX302),Phase 2
SPPI,03/31/2018,SPI-2012 (ROLONTIS),Phase 3
TCON,03/31/2018,TRC105 and Inlyta,Phase 2
TTPH,03/31/2018,Eravacycline (TP-434) - IGNITE3,Phase 3
VBLT,03/31/2018,VB-111,Phase 3
VICL,03/31/2018,ASP0113 Vaccine,Phase 3
VTVT,03/31/2018,Azeliragon - STEADFAST,Phase 3
ZFGN,03/31/2018,ZGN-1061,Phase 2
THERF,04/03/2018,Ibalizumab,PDUFA
LLY,04/12/2018,Abemaciclib - MONARCH 3,PDUFA priority review
RARE,04/17/2018,KRN23 Burosumab,PDUFA priority review
RIGL,04/17/2018,Fostamatinib,PDUFA
ABBV,04/27/2018,Elagolix,PDUFA priority review
NBIX,04/27/2018,Elagolix,PDUFA priority review
ALKS,04/30/2018,ALKS 3831 - ENLIGHTEN-2,Phase 3
AMGN,04/30/2018,KYPROLIS (ENDEAVOR),PDUFA
KPTI,04/30/2018,Selinexor - STORM,Phase 2b
NBRV,04/30/2018,Lefamulin - LEAP 2,Phase 3
AMGN,05/17/2018,Erenumab,PDUFA
NVS,05/17/2018,Erenumab,PDUFA
REPH,05/26/2018,Intravenous (IV) meloxicam,PDUFA
AMGN,05/28/2018,Prolia (denosumab),PDUFA
KTOV,05/31/2018,KIT-302,PDUFA
VRX,06/18/2018,IDP-118,PDUFA
ABBV,06/30/2018,Elagolix,Phase 3
ABBV,06/30/2018,Rova-T (TRINITY),Phase 2
ACRS,06/30/2018,ATI-50002,Phase 2
AGN,06/30/2018,ATOGEPANT,Phase 2b
AGN,06/30/2018,UBROGEPANT,Phase 3
AGN,06/30/2018,ESMYA  (ulipristal acetate),PDUFA
ALRN,06/30/2018,ALRN-6924,Phase 2a
AMGN,06/30/2018,ABP 798,Phase 3
ANAB,06/30/2018,ANB020,Phase 2a
ANIK,06/30/2018,Cingal,Phase 3
ARGS,06/30/2018,rocapuldencel-T (AGS-003) ADAPT Trial,Phase 3
ARRY,06/30/2018,Binimetinib - COLUMBUS,PDUFA
AVIR,06/30/2018,BTA074 5% topical gel,Phase 2
AXSM,06/30/2018,AXS-05 STRIDE-1,Phase 3
AZN,06/30/2018,Selumetinib - ASTRA,Phase 3
AZN,06/30/2018,PT010,Phase 3
AZN,06/30/2018,Lynparza,Phase 3
AZN,06/30/2018,Durvalumab +/- tremelimumab (MYSTIC),Phase 3
AZN,06/30/2018,Durvalumab +/- tremelimumab (KESTREL),Phase 3
AZN,06/30/2018,Durvalumab +/- tremelimumab (EAGLE),Phase 3
AZN,06/30/2018,Durvalumab +/- tremelimumab (ARCTIC),Phase 3
BHVN,06/30/2018,Rimegepant,Phase 3
BMY,06/30/2018,CM-651 – Opdivo + Yervoy,Phase 3
BMY,06/30/2018,CM-511 – Opdivo + Yervoy,Phase 3
BMY,06/30/2018,CM-451 – Opdivo + Yervoy,Phase 3
BMY,06/30/2018,CM-331– Opdivo,Phase 3
BMY,06/30/2018,CM-078 – Opdivo,Phase 3
BMY,06/30/2018,CM-548 - Opdivo+SOC,Phase 2
BOLD,06/30/2018,AT342 - VALENS,Phase 1/2
CLDX,06/30/2018,Glembatumumab vedotin,Phase 2b
CLSD,06/30/2018,Suprachoroidal CLS-TA - TYBEE,Phase 2
CLSD,06/30/2018,Suprachoroidal CLS-TA - HULK,Phase 1/2
CNAT,06/30/2018,Emricasan,Phase 2b
CORI,06/30/2018,Corplex Donepezil,Phase 3
CPRX,06/30/2018,Firdapse,Phase 3
CTIC,06/30/2018,PIXUVRI - PIX306 Trial,Phase 3
DBVT,06/30/2018,Viaskin Milk,Phase 2b
ESPR,06/30/2018,"Bempedoic acid - CLEAR LDL-C Lowering Program 1002-046, 1002-047 and 1002-048",Phase 3
ESPR,06/30/2018,Bempedoic acid (ETC-1002-040) - Clear Harmony,Phase 3
EXEL,06/30/2018,IMblaze370 - cobimetinib and atezolizumab,Phase 3
EYEG,06/30/2018,EGP-437,Phase 3
FBIO,06/30/2018,CEVA101,Phase 2
FBIO,06/30/2018,Pepvax vaccine,Phase 2
FBIO,06/30/2018,IV Tramadol,Phase 3
FLKS,06/30/2018,FLX-787,Phase 2
GEMP,06/30/2018,Gemcabene - INDIGO-1,Phase 2b
GILD,06/30/2018,Filgotinib - EQUATOR,Phase 2
GILD,06/30/2018,Selonsertib (GS-4997),Phase 2
GLMD,06/30/2018,Aramchol - ARREST,Phase 2b
GLPG,06/30/2018,Filgotinib - TORTUGA,Phase 2
GLPG,06/30/2018,Filgotinib - EQUATOR,Phase 2
GTHX,06/30/2018,G1T38 plus Faslodex,Phase 1b
IDRA,06/30/2018,IMO-8400,Phase 2
INCY,06/30/2018,Epacadostat with Keytruda - ECHO-301,Phase 3
INCY,06/30/2018,Ruxolitinib - REACH 1,Phase 3
JNCE,06/30/2018,JTX-2011,Phase 1/2
JNJ,06/30/2018,Esketamine,Phase 3
KURA,06/30/2018,Tipifarnib,Phase 2
MACK,06/30/2018,MM-141 - CARRIE,Phase 2
MDWD,06/30/2018,NexoBrid,Phase 3
MEIP,06/30/2018,Pracinostat in combination with Vidaza,Phase 2
MGNX,06/30/2018,Margetuximab in combination with pembrolizumab,Phase 2
MTNB,06/30/2018,MAT2501,Phase 2
NBIX,06/30/2018,Elagolix,Phase 3
NVS,06/30/2018,LEE011: MONALEESA-3,Phase 3
PBYI,06/30/2018,Neratinib,Phase 3
PFNX,06/30/2018,PF708 and Forteo,Phase 3
PRTA,06/30/2018,NEOD001 PRONTO,Phase 2b
PSTI,06/30/2018,PLX-PAD (stem cells),Phase 2
RNN,06/30/2018,RX-3117 in combination with Abraxane,Phase 2a
RXDX,06/30/2018,RXDX-105,Phase 1b
RYTM,06/30/2018,Setmelanotide,Phase 2
RYTM,06/30/2018,Setmelanotide,Phase 2
RYTM,06/30/2018,Setmelanotide,Phase 2
SBBP,06/30/2018,COR-003 (levoketoconazole) - SONICS,Phase 3
SGMO,06/30/2018,SB-525 cDNA gene therapy,Phase 1/2
SGMO,06/30/2018,SB-318,Phase 1/2
SGMO,06/30/2018,SB-FIX,Phase 1/2
SGMO,06/30/2018,SB-913 - CHAMPIONS,Phase 1/2
SNDX,06/30/2018,Entinostat plus Keytruda - ENCORE 601,Phase 1/2
SNDX,06/30/2018,E2112,Phase 3
SNGX,06/30/2018,SGX301 (synthetic hypericin),Phase 3
SVRA,06/30/2018,Aironite - INDIE,Phase 2
TBPH,06/30/2018,TD-9855,Phase 2a
TCON,06/30/2018,TRC253,Phase 1/2
TCON,06/30/2018,TRC105 and Nexavar,Phase 2
TGTX,06/30/2018,TG-1101 and TGR-1202 - UNITY-CLL study,Phase 3
TNXP,06/30/2018,TNX-102 SL,Phase 3
TOCA,06/30/2018,Toca 511 & Toca FC,Phase 2/3
TSRO,06/30/2018,Niraparib and Keytruda (TOPACIO),Phase 1/2
URGN,06/30/2018,MitoGel - OLYMPUS,Phase 3
VICL,06/30/2018,VCL-HB01 HSV-2 Therapeutic Vaccine,Phase 2
VKTX,06/30/2018,VK2809,Phase 2
VTGN,06/30/2018,AV-101,Phase 2
ZGNX,06/30/2018,ZX008 - Study 1504,Phase 3
ALNY,07/31/2018,Givosiran,Phase 3
BLRX,07/31/2018,BL-8040,Phase 2
BYSI,07/31/2018,Plinabulin (Trial 106),Phase 2/3
CELG,07/31/2018,Luspatercept - BELIEVE,Phase 3
CELG,07/31/2018,Luspatercept - MEDALIST,Phase 3
EBIO,07/31/2018,Vicinium,Phase 3
FOMX,07/31/2018,FMX103,Phase 3
FOMX,07/31/2018,FMX101 - FX2017-22,Phase 3
GNMX,07/31/2018,AEVI-001 (NFC-1),Phase 2
GNMX,07/31/2018,AEVI-002 (Anti-LIGHT mAb),Phase 1/2
LLY,07/31/2018,Ramucirumab,Phase 3
MRTX,07/31/2018,Sitravatinib plus nivolumab,Phase 2
OBSV,07/31/2018,OBE2109 - EDELWEISS,Phase 2b
RDHL,07/31/2018,RHB-104 MAP US,Phase 3
SCYX,07/31/2018,SCY-078 - oral,Phase 2
SNSS,07/31/2018,SNS-062,Phase 1/2
VNDA,07/31/2018,Tradipitant,Phase 2
XLRN,07/31/2018,Luspatercept - MEDALIST,Phase 3
XLRN,07/31/2018,Luspatercept - BELIEVE,Phase 3
AKCA,08/30/2018,Volanesorsen - APPROACH,PDUFA
ALXN,08/31/2018,Eculizumab,Phase 3
ONCS,08/31/2018,ImmunoPulse IL-12 - PISCES,Phase 2b
AGTC,09/30/2018,rAAV-hRS1,Phase 1/2
AMRN,09/30/2018,Vascepa REDUCE-IT outcomes trial,–
AQXP,09/30/2018,AQX-1125 LEADERSHIP,Phase 3
FLKS,09/30/2018,FLX-787 - COMMEND US trial,Phase 2
GILD,09/30/2018,F/TAF (Descovy),Phase 3
HSGX,09/30/2018,NeoCart,Phase 3
RGLS,09/30/2018,RG-012 - HERA,Phase 2
VTL,09/30/2018,VTI-308,Phase 3
CNCE,09/30/2018,AVP-786,Phase 3
ABBV,12/31/2018,ABT-494 - SELECT-COMPARE,Phase 3
ABBV,12/31/2018,Imbruvica - PHOENIX,Phase 3
ABUS,12/31/2018,"ARB-1467, tenofovir, and pegylated interferon",Phase 2
ACIU,12/31/2018,ACI-24 (anti-Abeta vaccine),Phase 1/2
ACRS,12/31/2018,ATI-50001,Phase 2
ACRS,12/31/2018,A-101,Phase 2b
ADVM,12/31/2018,ADVM-043,Phase 1/2
ADXS,12/31/2018,ADXS-PSA and Keytruda,Phase 1/2
AGLE,12/31/2018,AEB1102,Phase 1/2
AGN,12/31/2018,Brazikumab,Phase 2b
AGN,12/31/2018,Cariprazine,Phase 3
AGN,12/31/2018,ABICIPAR,Phase 3
AKBA,12/31/2018,Vadadustat - TRILO2GY,Phase 3
AKBA,12/31/2018,Vadadustat - FO2RWARD,Phase 2
AKCA,12/31/2018,AKCEA-APO(a)-LRx,Phase 2b
ALDX,12/31/2018,ADX-102,Phase 2b
ALDX,12/31/2018,ADX-102,Phase 3
ALDX,12/31/2018,ADX-102,Phase 2
ALNY,12/31/2018,ALN-CC5 (cemdisiran),Phase 1/2
ARGS,12/31/2018,ARGX-113,Phase 2
ARGX,12/31/2018,ARGX-113,Phase 2
ATNX,12/31/2018,Oraxol,Phase 3
AUPH,12/31/2018,Voclosporin,Phase 2
AUPH,12/31/2018,Voclosporin,Phase 2
AZN,12/31/2018,Farxiga - DECLARE,Phase 3
AZN,12/31/2018,Benralizumab - TERRANOVA,Phase 3
AZN,12/31/2018,Farxiga - DECLARE,Phase 3
AZN,12/31/2018,Durvalumab +/- tremelimumab (NEPTUNE),Phase 3
AZN,12/31/2018,Anifrolumab,Phase 3
BIIB,12/31/2018,Raxatrigine - BIIB074 (Nav1.7 inhibitor),Phase 2
BLPH,12/31/2018,INOpulse delivery device,Phase 2
BLPH,12/31/2018,INOpulse delivery device,Phase 3
BLRX,12/31/2018,BL-8040,Phase 2b
BMY,12/31/2018,CM-602 – Opdivo + Elo + SOC,Phase 3
BMY,12/31/2018,CM-459 – Opdivo,Phase 3
BYSI,12/31/2018,Plinabulin,Phase 3
CELG,12/31/2018,REVLIMID - ROBUST,Phase 3
CELG,12/31/2018,MM-007 OPTIMISMM,Phase 3
CELG,12/31/2018,Oral Azacitidine - CC-486-AML-001,Phase 3
CELG,12/31/2018,ABRAXANE - PANC-003 apact,Phase 3
CELG,12/31/2018,ABRAXANE - IMpower 130 ( I/O Combo),Phase 3
CELG,12/31/2018,ABRAXANE - IMpower 131 ( I/O Combo),Phase 3
CELG,12/31/2018,ABRAXANE - IMPassion ( I/O Combo),Phase 3
CFRX,12/31/2018,CF-301,Phase 2
CNAT,12/31/2018,Emricasan,Phase 2
CNCE,12/31/2018,CTP-543,Phase 2a
EARS,12/31/2018,AM-111 ASSENT,Phase 3
EIGR,12/31/2018,Exendin 9-39,Phase 2
EIGR,12/31/2018,Ubenimex - ULTRA,Phase 2
EPZM,12/31/2018,Tazemetostat,Phase 2
ESPR,12/31/2018,Bempedoic Acid/ Ezetimibe (1002FDC-053),Phase 3
FGEN,12/31/2018,Roxadustat - ANDES,Phase 3
FLKS,12/31/2018,FLX-787 (Aust),Phase 2
GEMP,12/31/2018,Gemcabene - AZURE-1,Phase 2
GILD,12/31/2018,GS-9876,Phase 2
GILD,12/31/2018,GS-5734,Phase 2
GILD,12/31/2018,Axicabtagene ciloleucel - KTE-C19 (ZUMA-2),Phase 2
GILD,12/31/2018,Axicabtagene ciloleucel - KTE-C19 (ZUMA-3),Phase 1/2
GILD,12/31/2018,Axicabtagene ciloleucel - KTE-C19 (ZUMA-4),Phase 1/2
GSK,12/31/2018,Closed Triple - CAPTAIN,Phase 3
GTXI,12/31/2018,Enobosarm,Phase 2
GWPH,12/31/2018,Epidiolex,Phase 3
HALO,12/31/2018,PEGPH20 - HALO-301,Phase 3
IMGN,12/31/2018,Kadcyla (KATHERINE).,Phase 3
IMRN,12/31/2018,IMM-529,Phase 1/2
INVA,12/31/2018,Closed Triple,Phase 3
IOVA,12/31/2018,LN-145,Phase 2
JNJ,12/31/2018,STELARA (USTEKINUMAB),Phase 3
KPTI,12/31/2018,Selinexor - SADAL,Phase 2b
LLY,12/31/2018,Flortaucipir F 18 (Tau imaging agent),Phase 3
MACK,12/31/2018,MM-121,Phase 2
MBRX,12/31/2018,Annamycin,Phase 1/2
MRK,12/31/2018,Epacadostat with Keytruda - ECHO-301,Phase 3
MRNS,12/31/2018,Ganaxolone,Phase 2
NBIX,12/31/2018,INGREZZA - T-Force GOLD,Phase 2b
NVCR,12/31/2018,Tumor Treating Fields (TTFields) STELLAR,Phase 2
NVS,12/31/2018,QVM149,Phase 3
OBSV,12/31/2018,OBE022 - PROLONG,Phase 2a
OCUL,12/31/2018,OTX-TP,Phase 3
PFE,12/31/2018,Tanezumab,Phase 3
PLX,12/31/2018,PRX-102,Phase 3
PRQR,12/31/2018,QR-010,Phase 1/2
PULM,12/31/2018,PUR1800,Phase 2
RDHL,12/31/2018,RHB-105 - ERADICATE Hp 2,Phase 3
RETA,12/31/2018,Bardoxolone methyl - CATALYST,Phase 3
RIGL,12/31/2018,Fostamatinib,Phase 2
SBBP,12/31/2018,COR-003 (levoketoconazole) - LOGICS,Phase 3
SGEN,12/31/2018,ADCETRIS in combination with chemotherapy - ECHELON-2,Phase 3
SNNA,12/31/2018,SNA-001,Phase 3
SNNA,12/31/2018,SNA-001,Phase 3
SVRA,12/31/2018,Molgradex - IMPALA,Phase 3
TBPH,12/31/2018,Closed Triple - CAPTAIN,Phase 3
TCON,12/31/2018,TRC105,Phase 2
TCON,12/31/2018,TRC102,Phase 2
TCON,12/31/2018,TRC105 (TAPPAS),Phase 3
UTHR,12/31/2018,Esuberaprost - BEAT,Phase 3
UTHR,12/31/2018,Orenitram,Phase 3
VNDA,12/31/2018,HETLIOZ (tasimelteon),Phase 3
VRNA,12/31/2018,RPL554,Phase 2b
VTGN,12/31/2018,AV-101,Phase 2
XBIT,12/31/2018,XBIO-101,Phase 2
XNCR,12/31/2018,XmAb5871,Phase 2
CLSD,03/31/2019,Suprachoroidal CLS-TA - SAPPHIRE,Phase 3
CLSN,03/31/2019,ThermoDox - OPTIMA,Phase 3
GSK,03/31/2019,Danirixin,Phase 2b
PRTO,03/31/2019,Vonapanitase (PRT-201) PATENCY-2,Phase 3
ABBV,06/30/2019,ABBV-8E12,Phase 2
ATNM,06/30/2019,Iomab-B,Phase 3
BMY,06/30/2019,CM-568 - Opdivo + Yervoy,Phase 2
CNAT,06/30/2019,Emricasan,Phase 2
FBIO,06/30/2019,CEVA101,Phase 2
GBT,06/30/2019,GBT440 - HOPE,Phase 3
GSK,06/30/2019,Tapinarof,Phase 3
GSK,06/30/2019,Inhaled PI3Kδ inhibitor,Phase 2b
ICPT,06/30/2019,Ocaliva (Obeticholic acid (OCA)) - REGENERATE,Phase 3
RYTM,06/30/2019,Setmelanotide,Phase 3
SNDX,06/30/2019,Entinostat plus Tecentriq - ENCORE 603,Phase 1/2
SNNA,06/30/2019,SNA-120,Phase 2b
TBPH,06/30/2019,Telavancin,Phase 3
AKBA,07/31/2019,Vadadustat - INNO2VATE,Phase 3
AKBA,07/31/2019,Vadadustat - PRO2TECT,Phase 3
ALNY,10/31/2019,Fitusiran (ATLAS),Phase 3
ABBV,12/31/2019,Venetoclax,Phase 3
AFMD,12/31/2019,AFM13,Phase 2
AGN,12/31/2019,RAPASTINEL,Phase 3
ANAB,12/31/2019,ANB020,Phase 2b
AZN,12/31/2019,AZD3293,Phase 3
AZN,12/31/2019,Durvalumab +/- tremelimumab (DANUBE),Phase 3
AZN,12/31/2019,Brilinta (THEMIS),Phase 3
BCLI,12/31/2019,NurOwn,Phase 3
BMRN,12/31/2019,Valoctocogene roxaparvovec (BMN 270),Phase 3
BMRN,12/31/2019,Vosoritide,Phase 3
CELG,12/31/2019,REVLIMID - MAGNIFY NHL-010,Phase 3
CHMA,12/31/2019,Mycapssa - OPTIMAL,Phase 3
CNAT,12/31/2019,Emricasan,Phase 2b
CRBP,12/31/2019,Anabasum (Resunab),Phase 3
GALE,12/31/2019,NeuVax in combination with Herceptin,Phase 2
GSK,12/31/2019,Mepolizumab - SYNAPSE,Phase 3
IMGN,12/31/2019,Kadcyla (KAITLIN),Phase 3
INCY,12/31/2019,Ruxolitinib - REACH 3,Phase 3
JNJ,12/31/2019,INVOKANA - CREDENCE,Phase 3
JNJ,12/31/2019,DARZALEX (Daratumumab),Phase 3
KPTI,12/31/2019,Selinexor - SEAL,Phase 2/3
KPTI,12/31/2019,Selinexor - BOSTON,Phase 3
MDCO,12/31/2019,Inclisiran,Phase 3
MRK,12/31/2019,MK-8931 (019) - Verubecestat,Phase 3
NVS,12/31/2019,QAW039 (fevipiprant),Phase 3
NVS,12/31/2019,OMB157 (ofatumumab),Phase 3
NVS,12/31/2019,Entresto - PARAGON,Phase 3
NVS,12/31/2019,Entresto - PARADISE,Phase 3
NVS,12/31/2019,AIN457 (Cosentyx),Phase 3
OBSV,12/31/2019,OBE2109 - PRIMROSE,Phase 3
RETA,12/31/2019,Bardoxolone methyl - CARDINAL,Phase 3
RETA,12/31/2019,Omaveloxolone - MOXIe,Phase 2
ABBV,06/30/2020,ABBV-8E12,Phase 2
ADXS,06/30/2020,Axalimogene filolisbac - AIM2CERV Trial,Phase 3
AGN,12/31/2020,RELAMORELIN,Phase 3
AZN,12/31/2020,Durvalumab (ADJUVANT),Phase 3
CATB,12/31/2020,Edasalonexent (CAT-1004),Phase 3
CELG,12/31/2020,REVLIMID - MAGNIFY NHL-008,Phase 3
CHMA,12/31/2020,Mycapssa - MPOWERED,Phase 3
GSK,12/31/2020,Daprodustat - ASCEND-D,Phase 3
INCY,12/31/2020,Ruxolitinib - REACH 2,Phase 3
NVCR,12/31/2020,Tumor Treating Fields (TTFields) METIS,Phase 3
NVS,12/31/2020,Ruxolitinib - REACH 2,Phase 3
PFE,12/31/2020,XTANDI,Phase 3
PRTA,12/31/2020,NEOD001 VITAL,Phase 3
PFE,06/30/2021,XTANDI (EMBARK),Phase 3
NVCR,12/31/2021,Tumor Treating Fields (TTFields) LUNAR,Phase 3
NVS,12/31/2023,CNP 520,Phase 2/3
